ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Show more
11682 El Camino Real, San Diego, CA, 92130, United States
Market Cap
801.3M
52 Wk Range
$6.66 - $18.90
Previous Close
$8.56
Open
$8.57
Volume
2,382,511
Day Range
$7.61 - $8.64
Enterprise Value
662.6M
Cash
245M
Avg Qtr Burn
-43.49M
Insider Ownership
16.75%
Institutional Own.
92.93%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria | Phase 2b Data readout | |
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer | Failed Discontinued |
